BRIEF-Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer

Lantern Pharma, Inc.

Lantern Pharma, Inc.

LTRN

0.00

June 2 (Reuters) - Lantern Pharma Inc LTRN.O:

  • LANTERN PHARMA REPORTS HARMONIC™ DATA SHOWING LP-300 PROGRESSION-FREE SURVIVAL BENEFIT DEEPENS WITH TREATMENT DURATION IN EGFR EXON 21 L858R LUNG CANCER

  • LANTERN PHARMA - REPORTS LP-300 PFS BENEFIT DEEPENS WITH TREATMENT DURATION IN L858R LUNG CANCER

  • LANTERN PHARMA - L858R NSCLC PATIENTS REACHED 8.9-MONTH MEDIAN PFS WITH LP-300; DURABLE RESPONSES BEYOND TWO YEARS

  • LANTERN PHARMA - LP-300 PLUS CHEMO SHOWS NO CLINICALLY MEANINGFUL TOXICITY BEYOND CHEMOTHERAPY

  • LANTERN PHARMA - OVER 70% OF L858R PATIENTS SHOW TUMOR REDUCTION; 77% CLINICAL BENEFIT RATE

Source text: ID:nBw3CnYbja

Further company coverage: LTRN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.